SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Political uncertainty ahead of the midterm elections and debate over the Iran conflict dominate discussion, with traders linking war and cost-of-living concerns to market pressure and DJTs decline. Bearish views prevail, though some speculate a peace deal or Republican win could improve sentiment.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to Iran-related tensions and reported threats to oil shipments through the Strait of Hormuz, which have fueled concerns about supply disruptions and supported crude prices. Bulls see further risk from possible escalation and depleted reserves, while bears expect a sharp pullback if negotiations produce a deal or tensions ease.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras antibody for menopausal hot flashes: traders are discussing its positive Phase 2 results and additional conference data while watching for longer-term durability results and clarity on a Phase 3 path. Bulls view the program as validation of AbCelleras pipeline, while skeptics say the latest presentation added little beyond known results and want more concrete clinical updates.

Select Sector SPDR Trust (The) - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

Traders are focused on the Iran conflict, Strait of Hormuz shipping risks and reported attacks on energy infrastructure, with concerns about disrupted oil and fuel supply supporting interest in energy stocks. The community is split between those expecting further gains if tensions persist and those warning that diplomacy, easing supply fears or profit-taking could reverse the rally.

ProShares Trust II - ProShares Ultra Bloomberg Crude Oil 2x Shares

ProShares Ultra Bloomberg Crude Oil

Hopes for U.S.-Iran de-escalation are weighing on crude prices and UCO, while persistent concerns about Strait of Hormuz disruptions and constrained supply keep some traders bullish. The community is debating whether diplomacy will ease the oil-risk premium or whether renewed conflict will sustain sharp swings.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Reports of advanced talks to acquire Lumentum have driven attention, with traders worried the large deal could require substantial share dilution or debt and weigh on Marvell. Some see strategic value in combining Marvells AI networking chips with Lumentums optical technology, but the talks remain unconfirmed and the market reaction has been sharply negative.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas negative S&P outlook, tied to heavy AI infrastructure spending and uncertainty about free cash flow, is driving concern alongside fears that planned stock sales could dilute shareholders. Traders debate whether strong advertising growth and potential AI monetization can justify the investment, with some viewing the selloff as a buying opportunity.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs upcoming Q3 report is the dominant focus, with traders debating whether strong results and raised guidance can clear an already high bar as AI stocks face a broader pullback. Bulls expect continued growth, while skeptics warn that a beat may not prevent selling given the stocks lofty valuation and risk-off sentiment.

ProShares Trust II - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is drawing attention as natural-gas weakness and repeated lows collide with hopes for a winter-weather rebound. Traders disagree over whether colder forecasts and tighter storage could spark a bounce, while others point to mild-weather expectations, ample supply, and the ETFs leverage and futures-roll decay as risks.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to a 52-week high has fueled buyout speculationoften centered on Sanofiand hopes for a short squeeze, with traders also pointing to heavy call-option activity. BRIUMVIs commercial growth and forthcoming earnings and subcutaneous data add to the optimism, while some traders doubt a deal is imminent and see the rally as momentum ahead of results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cencora Gears Up to Report Q4 Results: How to Play the Stock?

COR's Q4 earnings are likely to benefit from strong specialty pharma demand and MSO growth, but pricing pressures and higher interest costs may weigh on results.

Revvity Gears Up to Post Q3 Earnings: What's in Store for the Stock?

RVTY's Q3 earnings may gain from recovering pharma demand, stronger HCS demand and software growth, despite lingering spending and TB-related headwinds.

STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?

STE's second-quarter fiscal 2027 earnings may benefit from Healthcare growth, recent acquisitions, easing AST comparisons and continued margin expansion.

BTSG Ahead of Q3 Earnings: Can Growth Offset Ongoing IRA Risks?

BrightSpring gears up for Q3 earnings, with strong Specialty, Infusion and Provider Services growth expected to offset IRA headwinds. Can it beat estimates?

Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?

ZBH heads into Q3 earnings with growth expected in Hips, S.E.T. and Technology & Data, while Knee sales face ongoing pressure.

Waters Gears Up to Report Q3 Results: How to Play the Stock?

WAT's Q3 results are likely to benefit from strong revenue growth prospects, rising demand and acquisition gains.

NTRA Q3 Earnings on Deck: Will Signatera Volume Growth Drive Results?

Natera's third-quarter 2026 results hinge on Signatera volume growth, regulatory milestones and higher test prices, while expanding Medicare coverage may boost organ health revenues.

Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Veracyte (VCYT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ACB's Q2 Earnings on Deck: International Medical Cannabis in Focus

Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.

DexCom Gears Up to Report Q3 Results: How to Play the Stock?

DXCM Q3 earnings are likely to benefit from CGM adoption, G7 15 Day uptake and wider reimbursement amid tougher international comparisons.

IDEXX Laboratories, Inc. engages in the development, manufacturing, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing industries. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983 and is headquartered in Westbrook, ME.

Idexx Laboratories, Inc.

IDEXX Reports Upbeat Q1 Profit, Upgrades Full-Year Guidance: Retail’s Positive

Equity

Bearish Sentiment

Shares of IDEXX Laboratories, Inc. (IDXX) traded 9% higher on Thursday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.idexx.com/files/2025-q1-earnings-release-20250501.pdf">reported</a> upbeat first-quarter profit and raised its annual forecast.The veterinary diagnostics company’s first-quarter (Q1) revenue came in at $998 million, marking an increase of 4% year-on-year (YoY), but below an analyst estimate of $999.52 million, as per Finchat data.Diluted earnings per share came in at $2.96, up from $2.81 in the corresponding period of 2024, and exceeding an estimated $2.84.The company adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.IDEXX also updated its full-year EPS outlook to $11.93 to $12.43, up from previous guidance of $11.74 to $12.24. The new earnings guidance includes a favorable adjustment to a now-concluded litigation matter expense accrual, the company said.The firm also updated its full-year operating margin outlook to 31.1% to 31.6% from 31% to 31.5%, including estimates for the impact of tariffs.The new estimates include tariffs on internationally sourced materials, based on current U.S. pronouncements and forecasts for China’s retaliatory tariffs, the company said.On Stocktwits, retail sentiment around IDEXX fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume jumped from ‘extremely low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:631/69;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_01_at_1_42_40_PM_png_db37931bed.webp" alt="IDXX's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 1, 2025 | Source: Stocktwits" width="631" height="69"><figcaption>IDXX's Sentiment Meter and Message Volume as of 1:40 p.m. ET on May 1, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/IDXX">IDXX stock</a> is up by over 15% so far this year and by nearly 1% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/byd-reports-21-percent-jump-in-ev-sales-in-april/chLvX7XRb0R">BYD Reports 21% Jump In April EV Sales: Retail’s Optimistic</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The company has adjusted its full-year revenue guidance to $4.1 billion to $4.21 billion, reflecting the benefits of foreign exchange impacts, up from its previous estimate of $4.06 billion to $4.17 billion.

Idexx Laboratories Inc

Vanguard S&P 500 ETF

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$551.21
Prev Close	$575.98
Open	$583.75
Dividend Yield	0.00%
50-Day Moving Average	$534.27
Beta	0.95
Avg. Volume	508,656.50
PE Ratio	38.74

52-Week High	$769.98
52-Week Low	$500.61
Market Capitalization	$43.42B
EPS (Annual)	$13.08
Price to Book	26.96
Revenue Per Employee	$391,245.64

Feed

News

Sentiment

Earnings

Fundamentals

Info

IDXX Fundamentals